ライフサイエンスコーパス: MBq

1 97% and molar activity of approximately 14.0 MBq nmol(-1) Both radiotracers were immunoreactive and s

2 (82)Rb or (13)N-ammonia (1,100-3,000 MBq) was injected into the heart wall insert of an anthr

3 The risk of death decreased by 17% per 1,000-MBq increase in the total applied activity.

4 sease progression decreased by 13% per 1,000-MBq increase in the total applied activity.

5 an doses of note were the liver (6.02E-02mSv/MBq), kidneys (5.26E-02 mSv/MBq), and gallbladder (4.05E

6 .15E-03 mSv/MBq) and red marrow (8.49E-04mSv/MBq).

7 red a very low activity of (124)I-MIBG (1.05 MBq/kg), the effective dose was only approximately twice

8 /CT, and whole-body (124)I-MIBG PET/CT (1.05 MBq/kg).

9 The higher dose, 11.1 MBq, eradicated the tumor but had no effect on survival

10 mated maximum tolerated activity was about 1 MBq/kg.

11 MBq/200 pmol) versus high ( approximately 1 MBq/10 pmol) peptide amount of (177)Lu-NeoBOMB1, after w

12 l (68)Ga-NeoBOMB1 or a low ( approximately 1 MBq/200 pmol) versus high ( approximately 1 MBq/10 pmol)

13 )F-sodium fluoride ((18)F-NaF) at 248 +/- 10 MBq (mean +/- SD) and then a coronary CT angiography sca

14 6), and a decrease in injected activity (-10 MBq: OR, 1.28; 95% CI, 1.07-1.52).

15 d dose was the kidney (47.3 +/- 10.2 mGy/100 MBq).

16 uch as somatostatin analogs (2.1-2.6 mSv/100 MBq) and are beneficial for application as a research to

17 After intravenous injection of 100 MBq of the tracer, 4 successive PET/CT scans were obtain

18 0.07 mSv for a standard injected dose of 100 MBq).

19 The effective dose per a 100-MBq administered activity of (18)F-FAPI-74 was 1.4 +/- 0

20 ution (7 d after tracer administration, 1.11 MBq/animal, n = 4-6/group) was performed in wild-type an

21 either 165 MBq (129-232 MBq, n = 10) or 110 MBq (82-116 MBq, n = 10), whereas control mice were inje

22 on was reduced by 55% (P = 0.034) in the 110-MBq and by 88% (P < 0.01) in the 165-MBq group.

23 Patients received approximately 111 MBq (3 mCi) of (89)Zr-IAB22M2C (at minibody mass doses o

24 12 patients divided into 3 dose groups (111 MBq [3.0 mCi], 148 MBq [4.0 mCi], and 185 MBq [5.0 mCi]

25 h radioactivity concentrations as low as 114 MBq/mL (3.1 mCi/mL), which is sufficient for analysis of

26 peak of the NECR curve was 430 kcps (at 115 MBq) with the ratlike phantom and 78 kcps (at 139 MBq) w

27 MBq (129-232 MBq, n = 10) or 110 MBq (82-116 MBq, n = 10), whereas control mice were injected with ve

28 (177)Lu-PSMA-617 (120 MBq) with high specific activity induced superior tumor

29 (18)F-FDG and imaged with an additional 120 MBq of (177)Lu and repeated with shields surrounding the

30 l resolution and quantification of up to 120 MBq of (177)Lu activity (maximum activity tested).

31 ogy, an intravenous injection of 385 +/- 125 MBq of (99m)Tc-ADAPT6 was performed, randomized to an in

32 e were injected with either approximately 13 MBq/250 pmol (68)Ga-NeoBOMB1 or a low ( approximately 1

33 with the ratlike phantom and 78 kcps (at 139 MBq) with the monkeylike phantom.

34 sults: The dose-ranging study identified 148 MBq (4.0 mCi) as the optimal dose to obtain diagnostic-q

35 d into 3 dose groups (111 MBq [3.0 mCi], 148 MBq [4.0 mCi], and 185 MBq [5.0 mCi] +/- 10%) to determi

36 quality and accurate images at a dose of 148 MBq (4.0 mCi) for the detection of somatostatin-expressi

37 for up to 4 h after injection of 184 +/- 15 MBq of (18)F-TFB.

38 fter single (30 MBq) or fractionated (2 x 15 MBq, 2 wk apart) administrations.

39 a single intravenous injection or as two 15-MBq fractions 2 wk apart.

40 Injection of 150 MBq of (68)Ga-DOTA-Siglec-9 would expose a subject to 3.

41 whole-body immuno-PET after injection of 150 MBq of (68)Ga-IMP288, a histamine-succinyl-glycine pepti

42 Patients received a single 150-MBq intravenous injection of (68)Ga-DOTATOC (15 mug of p

43 DOTATOC (15 mug of peptide) and 2 single 150-MBq intravenous injections of (68)Ga-OPS202 (15 mug of p

44 Patients received 2 single 150-MBq intravenous injections of (68)Ga-OPS202 3-4 wk apart

45 n after (18)F-FDG administration (370 +/- 16 MBq).

46 harmaceutical in a median dose of either 165 MBq (129-232 MBq, n = 10) or 110 MBq (82-116 MBq, n = 10

47 the 110-MBq and by 88% (P < 0.01) in the 165-MBq group.

48 subjects after a bolus injection of 152-169 MBq of (18)F-MK-6240 to evaluate tracer kinetics and dis

49 , the effect of (213)Bi-IMP288 (6, 12, or 17 MBq) and (177)Lu-IMP288 (60 MBq) on tumor growth and sur

50 Mice receiving 17 MBq (213)Bi-IMP288 showed significant weight loss, resul

51 ous injection of (68)Ga-PSMA (mean dose, 176 MBq).

52 ons and then under the illumination of a 183 MBq (63)Ni radioisotope beta particle source.

53 A mean activity of 184 MBq was administered to 10 patients with metastatic HER2

54 vity was 1,469 +/- 428 MBq (range, 847-2,185 MBq), achieving a mean absorbed radiation dose to tumor

55 y administering doses in the range of 37-185 MBq as recommended incurrent guidelines.

56 11 MBq [3.0 mCi], 148 MBq [4.0 mCi], and 185 MBq [5.0 mCi] +/- 10%) to determine the lowest dose of (

57 prospectively imaged using approximately 185 MBq/10 mg of (89)Zr-DFO-MSTP2109A.

58 In human PET studies, [(18) F]Nifene (185 MBq; <0.10 mug) was well tolerated with no adverse effec

59 ET and wbPET following administration of 186 MBq and 307 MBq [(18)F]FDG on separate days, respectivel

60 hat SUVs remain stable down to 1/3 dose (1.2 MBq/kg).

61 m fluoride-NOTA-Z(EGFR:03115) (12 mug, 1.5-2 MBq/mouse) was used to monitor receptor changes.

62 G therapy, standard (123)I-MIBG imaging (5.2 MBq/kg) was performed on 7 patients, including whole-bod

63 after previous treatment were administered 2 MBq of (18)F-PSMA-11 per kilogram of body weight and the

64 by defining malignant lesions in doses of 2 MBq/kgBW and the maximum dose image (gold standard).

65 s were identified correctly with a dose of 2 MBq/kgBW; Likert scores did not differ significantly.

66 with a stable SUVpeak in all cases down to 2 MBq/kgBW.

67 tween 1.25 and 2.75 MBq/kgBW compared with 2 MBq/kgBW.

68 of activity per body weight (10, 15, and 20 MBq/kg).

69 This dose decreased to 0.77 +/- 0.11 mSv/20 MBq for 1-y-old children and 0.59 +/- 0.05 mSv for an in

70 2.32 +/- 0.32 mSv for an injected dose of 20 MBq in newborns.

71 of saline, 30 MBq of (177)Lu-DOTATOC, or 20 MBq of (177)Lu-DOTA-JR11 with an interval of 3 wk.

72 dose of 5.3 mSv for an administration of 200 MBq (5.4 mCi) of (68)Ga-FAPI-46 (1.56 +/- 0.26 mSv from

73 dose of 5.3 mSv for an administration of 200 MBq (5.4 mCi) of (68)Ga-FAPI-46 (1.56+/- 0.26 mSv from t

74 Thus for administration of 200 MBq (68)Ga-FAPI-46 the effective total body dose is 1.56

75 ENs scanned 1 and 3 h after injection of 200 MBq of (64)Cu-DOTATATE.

76 and (68)Ga-PSMA-11, an examination with 200 MBq of (68)Ga-FAPI-2 or (68)Ga-FAPI-4 corresponds to an

77 Ga-NOTA-AE105 (154 +/- 59 MBq; range, 48-208 MBq).

78 peritoneal treatment with escalating (20-215 MBq/L) activity concentrations of (211)At-MX35 F(ab')(2.

79 activity concentration was escalated to 215 MBq/L without any dose-limiting toxicities.

80 PSMA-7.3 (mean activity, 220; range, 210-228 MBq).

81 in a median dose of either 165 MBq (129-232 MBq, n = 10) or 110 MBq (82-116 MBq, n = 10), whereas co

82 ncers) were injected intravenously with 9.25 MBq of (86)Y-NM600 and imaged longitudinally over 4-5 d

83 ve C57BL/6 mice that were injected with 9.25 MBq of (90)Y-NM600 at 5, 10, and 28 d after injection.

84 uired 60 min after administration of 150-250 MBq of (68)Ga-labeled FAP-specific tracers.

85 n PET acquisition 2 h after injection of 250 MBq of (18)F-AV-133, and the resulting images were quant

86 , and 3 h after administration of 259 +/- 26 MBq of (18)F-FAPI-74.

87 luate one examination after injection of 263 MBq of (68)Ga-FAPI-74.

88 Patients received 174 +/- 28 MBq of the radiotracer, which was well tolerated in all

89 cohort (n = 7) was injected with 165 +/- 29 MBq (injected protein mass, 250 mug), and imaging was pe

90 98% and a specific activity of more than 292 MBq/mg.

91 A drawn dose of 8 mCi (296 MBq) of technetium 99m sestamibi was administered to all

92 activity: 135-380 MBq [range], 241 +/- 47.3 MBq [mean +/- SD]).

93 n +/- SD]) received a single weight-based (3 MBq/kg) (18)F-FDG injected activity (weight: 45-123 kg [

94 (68)Ga-NeoBOMB1 (3 MBq/kg of body weight) was injected intravenously, and s

95 tients were enrolled and received a single 3 MBq/kg injected dose of (18)F-FDG followed by a dual-ima

96 Flood histogram data were acquired using a 3-MBq (22)Na source to characterize crystal identification

97 0.59 +/- 0.05 mSv for an injected dose of 30 MBq in 5-y-old children.

98 T was assessed, comparing the efficacy of 30 MBq of (67)Cu-CuSarTATE or (177)Lu-LuTATE, either as a s

99 ravenous injections of 100 muL of saline, 30 MBq of (177)Lu-DOTATOC, or 20 MBq of (177)Lu-DOTA-JR11 w

100 Survival was comparable after single (30 MBq) or fractionated (2 x 15 MBq, 2 wk apart) administra

101 The therapeutic efficacy of a single 30-MBq dose of (19)F/(177)Lu-rhPSMA-7.3 (n = 7) was compare

102 following administration of 186 MBq and 307 MBq [(18)F]FDG on separate days, respectively.

103 was performed 1 h after injection of 122-312 MBq of (68)Ga-FAPI-04.

104 min after injection of a median dose of 313 MBq of (18)F-DCFPyL (range, 292-314 MBq).

105 e of 313 MBq of (18)F-DCFPyL (range, 292-314 MBq).

106 (18)F-DCFPyL PET/CT scans (median dose, 317 MBq; uptake time, 120 min) within a median of 4 d (range

107 injected activity of (18)F-rhPSMA-7 was 327 MBq (range, 132-410 MBq), with a median uptake time of 7

108 63 +/- 24 min after injection of 256 +/- 33 MBq of (18)F-flubrobenguane.

109 injected activity of (18)F-rhPSMA-7 was 336 MBq, with a median uptake time of 76 min.

110 h (177)Lu-lilotomab-satetraxetan (150 or 350 MBq/kg) and rituximab (4 x 10 mg/kg) were compared with

111 The combination of rituximab with 350 MBq/kg (177)Lu-lilotomab-satetraxetan synergistically su

112 ection of (18)F-SKI (mean, 241.24 +/- 116.36 MBq) as part of a prospective study.

113 with (64)Cu-labeled trastuzumab (0.016-0.368 MBq/mug, 67 nM) for 18 h versus the absorbed dose follow

114 oses of (99m)Tc-MAG3 in the range of 300-370 MBq (approximately 8-10 mCi) do not affect the relative

115 45 (291 +/- 67 MBq) and 1-min (15)O-H2O (370 MBq) scans were obtained in 35 age-matched elderly subje

116 min after intravenous administration of 370 MBq flortaucipir (18F).

117 tive dose was estimated at 6.9 mSv for a 370-MBq (18)F-FTT dose in humans.

118 Our dosimetry data showed that a 370-MBq injection of (18)F-FAZA is safe for clinical use, si

119 uired as 4 x 5 min frames 80 min after a 370-MBq injection, were motion-corrected, averaged, and tran

120 tely followed by PET/MRI, using a single 370-MBq (18)F-FDG dose.

121 1 +/- 15 kg [mean +/- SD]; activity: 135-380 MBq [range], 241 +/- 47.3 MBq [mean +/- SD]).

122 min after intravenous injection of 162 +/- 4 MBq of (68)Ga-DOTA-Siglec-9.

123 Doses of 3.7 and 7.4 MBq extended survival to 55 and 58 d, respectively, caus

124 tion of 133.2-151.7 MBq (mean, 140.6 +/- 7.4 MBq) of (68)Ga-RM2 using a time-of-flight-enabled simult

125 ith a specific radioactivity of 81.4 +/- 7.4 MBq/mg (2.2 +/- 0.2 muCi/mg).

126 s), immediately followed by approximately 40 MBq of one of the (89)Zr-labeled antibodies injected int

127 +/- SD, 61 +/- 16 y) ranged from 145 to 405 MBq (mean +/- SD, 268 +/- 59.3).

128 er infusion of the (111)In-DOTA-BC8 (176-406 MBq) into 52 adult patients with hematologic malignancie

129 s from simulated low-dose regimens (1.9-0.41 MBq/kg) were evaluated using several metrics: SUV quanti

130 f (18)F-rhPSMA-7 was 327 MBq (range, 132-410 MBq), with a median uptake time of 79.5 min (range, 60-1

131 administered radioactivity was 1,469 +/- 428 MBq (range, 847-2,185 MBq), achieving a mean absorbed ra

132 ganglioma/pheochromocytoma) received 148-444 MBq (4-12mCi) of (18)F-MFBG intravenously followed by se

133 e administered dose can be decreased to 2.46 MBq/kg, a 33% reduction in PET activity, with no degrada

134 92 +/- 26 min after injection of 301 +/- 46 MBq of (18)F-PSMA-1007.

135 whole-body PET/MRI examination from 3 to 0.5 MBq/kg of body weight (kgBW) in intervals of 0.25.

136 %, and a molar activity of approximately 1.5 MBq nmol(-1) Reaction optimization improved the radioche

137 re injected intravenously with 232.4 +/- 1.5 MBq of (18)F-clofarabine.

138 d a nonlinear increase, pronounced below 1.5 MBq/kgBW.

139 as 11.1 kcps and peaked at 20.8 kcps at 14.5 MBq.

140 ole-body (18)F-DCFPyL PET/CT (299.9 +/- 15.5 MBq) at 2 h after injection.

141 whole-body (18)F-DCFPyL-PET/CT (299.9+/-15.5 MBq) at 2 h p.i.

142 (n = 5-6) received excipient or 9.25 or 18.5 MBq of (177)Lu-NM600 as a single or fractionated schedul

143 activities used for treatment (9.25 and 18.5 MBq) were well tolerated, and only mild transient cytope

144 naive BALB/C mice administered 9.25 or 18.5 MBq.

145 60 min after injection (mean dose, 207 +/- 5 MBq).

146 by the administration of 18.5, 37.0, or 55.5 MBq of [(67)Cu]Cu-MeCOSar-Tz produced a dose-dependent t

147 semiefficient doses of (177)Lu-DOTATATE (7.5 MBq, intravenously) or the nicotineamide phosphoribosylt

148 h after injection of (125)I-pentixafor (7.5 MBq/kg).

149 proliferation under optimised conditions (5 MBq/mL, 60 min).

150 single administration of (67)Cu-CuSarTATE (5 MBq), tumor growth was inhibited by 75% compared with ve

151 Administration of (177)Lu-LuTATE (5 MBq) inhibited tumor growth by 89%.

152 Methods: Ten healthy volunteers received 50 MBq of (111)In-exendin-4, in combination with Gelofusine

153 e administered activity may be reduced to 50 MBq, resulting in an effective dose of less than 1 mSv f

154 Each received an injection of 278-527 MBq of (18)F-ISO-1 and then underwent PET/CT imaging of

155 maging and tissue biodistribution using 5.55 MBq (150 muCi) of (18)F-FES.

156 A 10-fold-lower injected dose of 0.555 MBq (15 muCi) of (18)F-FES was also used for tissue biod

157 venous dose of (68)Ga-NOTA-AE105 (154 +/- 59 MBq; range, 48-208 MBq).

158 g (89)Zr-deferoxamine-Z(EGFR:03115) (2.4-3.6 MBq, 2 mug) either together with or 30 min after increas

159 88 (6, 12, or 17 MBq) and (177)Lu-IMP288 (60 MBq) on tumor growth and survival was assessed.

160 Dynamic 60-min (18)F-AV45 (291 +/- 67 MBq) and 1-min (15)O-H2O (370 MBq) scans were obtained i

161 +/- 6.8 min) after injection of 133.2-151.7 MBq (mean, 140.6 +/- 7.4 MBq) of (68)Ga-RM2 using a time

162 count rate from a mouse-sized phantom at 3.7 MBq was 11.1 kcps and peaked at 20.8 kcps at 14.5 MBq.

163 red image data using a dosing regimen of 3.7 MBq/kg, images from simulated low-dose regimens (1.9-0.4

164 ime-point (18)F-fluciclovine (364.1 +/- 37.7 MBq) PET/CT from pelvis to diaphragm.

165 njected activity of (99m)Tc-PSMA I&S was 717 MBq (range: 562-828 MBq).

166 ific activity of approximately 2.24 +/- 0.74 MBq/mug (60.54 +/- 20 muCi/mug).

167 Patients were imaged with approximately 74 MBq of intraventricular (124)I-omburtamab via an Ommaya

168 A prior tracer dose of IP 74 MBq(124)I-omburtamab was used for radioimmuno-positron e

169 Study participants received 74 MBq (2 mCi) of intravenous (89)Zr-DFO-daratumumab.

170 ents received 740 MBq/1.7 m(2) (maximum, 740 MBq [20 mCi/1.7 m(2); maximum, 20 mCi]) of (11)C-methion

171 er a minimum 4-h fast, patients received 740 MBq/1.7 m(2) (maximum, 740 MBq [20 mCi/1.7 m(2); maximum

172 as stable over a range between 1.25 and 2.75 MBq/kgBW compared with 2 MBq/kgBW.

173 protocols using (18)F-DCFPyL (n = 62, 269.8 MBq, PET scan at 120 min after injection) or (68)Ga-PSMA

174 s after intravenous injection with 362 +/- 8 MBq of CTT1057 to evaluate the kinetics of CTT1057 and e

175 or up to 3 h after injection (357.2 +/- 48.8 MBq).

176 5)Ac-PSMA-I&T were applied (median dose, 7.8 MBq; range, 6.0-8.5), with 1 cycle in 3 patients, 2 cycl

177 of a 50-mug total of CAIX ligand and 600-800 MBq of (99m)Tc-PHC-102.

178 id intravenous bolus injection of 232 +/- 82 MBq of (18)F-FGln, followed by 2 static PET scans at 97

179 (99m)Tc-PSMA I&S was 717 MBq (range: 562-828 MBq).

180 TA-daratumumab, the lowest tested dose, 1.85 MBq, extended survival from 37 to 47 d but did not delay

181 f (15)O for an average patient dose of 1,850 MBq (50 mCi) in 10 mL.

182 tion) or (68)Ga-PSMA-HBED-CC (n = 129, 158.9 MBq, 60 min after injection).

183 ntom was 44 kcps for a total activity of 2.9 MBq (78 muCi), and the scatter fraction was 11%.

184 18)F-FDG PET/CT after injection of 210 +/- 9 MBq of (18)F-FDG.

185 isition after administration of 42.1 +/- 3.9 MBq of (18)F-FMISO by tail vein injection.

186 h after intravenously administered (38 +/- 9 MBq) (131)I-GMIB-anti-HER2-VHH1.

187 n of (18)F-AlF-PSMA-11 (0.26 nmol/mouse, 8-9 MBq/mouse) in male BALB/c nude mice with PSMA-expressing

188 vely, with molar activity of more than 0.925 MBq/nmol.

189 ne transporter radioligand (18)F-FE-PE2I (94 MBq) to evaluate the in vivo performance of the system.

190 1.4 cGy/MBq for spleen, 0.055 +/- 0.014 cGy/MBq for total body, 0.21 +/- 0.15 cGy/MBq for osteogenic

191 4)I-omburtamab samples and 0.07 +/- 0.04 cGy/MBq for (131)I-omburtamab samples.

192 bed dose to the blood was 0.051 +/- 0.11 cGy/MBq for (124)I-omburtamab samples and 0.07 +/- 0.04 cGy/

193 for osteogenic cells, and 0.17 +/- 0.15 cGy/MBq for kidneys.

194 14 cGy/MBq for total body, 0.21 +/- 0.15 cGy/MBq for osteogenic cells, and 0.17 +/- 0.15 cGy/MBq for

195 .40 cGy/MBq, compared with 2.22 +/- 2.19 cGy/MBq based on (124)I-omburtamab CSF samples and 1.53 +/-

196 ion of (90)Y-DOTA-BC8 were 0.35 +/- 0.20 cGy/MBq for red marrow, 0.80 +/- 0.24 cGy/MBq for liver, 3.0

197 20 cGy/MBq for red marrow, 0.80 +/- 0.24 cGy/MBq for liver, 3.0 +/- 1.4 cGy/MBq for spleen, 0.055 +/-

198 omburtamab CSF samples and 1.53 +/- 1.37 cGy/MBq based on (131)I-omburtamab CSF samples.

199 +/- 0.24 cGy/MBq for liver, 3.0 +/- 1.4 cGy/MBq for spleen, 0.055 +/- 0.014 cGy/MBq for total body,

200 the CSF for (131)I-8H9 of 0.62 +/- 0.40 cGy/MBq, compared with 2.22 +/- 2.19 cGy/MBq based on (124)I

201 Gy/MBq) and to bone marrow (0.31 +/- 0.05 Gy/MBq).

202 doses of 2.04 +/- 0.32 and 1.68 +/- 0.06 Gy/MBq to 4T07 and 4T1 tumors, respectively, which were lar

203 n those delivered to liver (1.28 +/- 0.09 Gy/MBq) and to bone marrow (0.31 +/- 0.05 Gy/MBq).

204 was 0.39, 0.44, 0.58, 0.1, 0.06, and 0.11 Gy/MBq, respectively.

205 of 2.72 +/- 0.33 Gy/MBq and 2.67 +/- 0.32 Gy/MBq, respectively.

206 to tumor dose estimates of 2.72 +/- 0.33 Gy/MBq and 2.67 +/- 0.32 Gy/MBq, respectively.

207 red by (90)Y-NM600 per injected activity (Gy/MBq) were estimated.

208 he 10 3D PET systems if the maximum injected MBq/kg values are respected to limit peak dead-time loss

209 int source), a NEMA sensitivity of 16.4 kcps/MBq, and a NEMA peak noise-equivalent count-rate of 306

210 These include sensitivity of 55 kcps/MBq, spatial resolution of 4.0 mm, energy resolution of

211 and to bone marrow it was 0.03 +/- 0.01 mGy/MBq.

212 ed dose of the salivary glands was 0.015 mGy/MBq.

213 d liver exposure of 0.10, 0.65, and 0.06 mGy/MBq, respectively.

214 hibited the highest absorbed dose, 0.067 mGy/MBq.

215 marrow was 0.13, 0.086, 0.33, and 0.068 mGy/MBq after rhTSH and 0.11, 0.14, 0.22, and 0.080 mGy/MBq

216 er rhTSH and 0.11, 0.14, 0.22, and 0.080 mGy/MBq after THW for each patient, respectively.

217 all, with median values of 1.37 and 1.12 mGy/MBq, respectively.

218 /MBq), and the heart wall (1.22 +/- 0.16 mGy/MBq), with an average effective dose of 0.54 +/- 0.07 mS

219 an +/- SD) were the liver (1.75 +/- 0.21 mGy/MBq), the kidneys (1.27 +/- 0.28 mGy/MBq), and the heart

220 ed dose to the kidneys was 1.54 +/- 0.25 mGy/MBq, and to bone marrow it was 0.03 +/- 0.01 mGy/MBq.

221 .21 mGy/MBq), the kidneys (1.27 +/- 0.28 mGy/MBq), and the heart wall (1.22 +/- 0.16 mGy/MBq), with a

222 9 mGy/MBq for arm 1 (lilotomab+) and 1.5 mGy/MBq for arm 2 (lilotomab-).

223 tion dose was received by the liver (0.5 mGy/MBq), followed by the spleen and kidneys.

224 en, with doses ranging from 1.54 to 3.60 mGy/MBq.

225 he source organs investigated, 0.16-0.79 mGy/MBq.

226 The mean absorbed doses to RM were 0.9 mGy/MBq for arm 1 (lilotomab+) and 1.5 mGy/MBq for arm 2 (li

227 The highest absorbed dose estimates (mGy/MBq) in normal tissues were to the right colon (0.167 +/

228 The effective dose was 0.0326 +/- 0.0018 mSv/MBq.

229 were 0.009 +/- 0.002 and 0.010 +/- 0.003 mSv/MBq for injected protein masses of 500 and 1,000 mug, re

230 tive dose was 0.0258 mSv/MBq (SD, 0.0034 mSv/MBq).

231 with the RADAR manual method and 0.0052 mSv/MBq with OLINDA/EXM.

232 rage radiation effective dose was 0.0055 mSv/MBq with the RADAR manual method and 0.0052 mSv/MBq with

233 46 mSv/MBq) and kidneys (0.029 +/- 0.009 mSv/MBq).

234 stimated human absorbed dose of 2.20E-01 mSv/MBq.

235 ata, the human effective dose was 0.0105 mSv/MBq.

236 The calculated effective dose was 0.0141 mSv/MBq when using a 3.5-h voiding interval.

237 the effective dose from 0.0908 to 0.0184 mSv/MBq and decreased the uptake in the liver, bone marrow,

238 quivalent dose was calculated as 9.6E-02 mSv/MBq for [(55)Co]Co-DOTATATE.

239 ver (6.02E-02mSv/MBq), kidneys (5.26E-02 mSv/MBq), and gallbladder (4.05E-02 mSv/MBq).

240 E-02 mSv/MBq), and gallbladder (4.05E-02 mSv/MBq).

241 was the urinary bladder wall at 7.96E-02 mSv/MBq.

242 The mean effective dose was 2.07E-02 mSv/MBq.

243 The mean effective dose was 0.022 mSv/MBq (range, 0.020-0.024 mSv/MBq).

244 e average total effective dose was 0.023 mSv/MBq.

245 se was 0.022 mSv/MBq (range, 0.020-0.024 mSv/MBq).

246 The effective dose was 0.0258 mSv/MBq (SD, 0.0034 mSv/MBq).

247 mSv/MBq), followed by ovaries (1.15E-03 mSv/MBq) and red marrow (8.49E-04 mSv/MBq).

248 mSv/MBq), followed by ovaries (1.15E-03 mSv/MBq) and red marrow (8.49E-04mSv/MBq).

249 ve doses were the bladder wall (2.41E-03 mSv/MBq), followed by ovaries (1.15E-03 mSv/MBq) and red mar

250 ective doses were bladder wall (2.41E-03 mSv/MBq), followed by ovaries (1.15E-03 mSv/MBq) and red mar

251 rahydrouridine was 2.12E-02 +/- 4.15E-03 mSv/MBq.

252 e effective total body dose was 7.80E-03 mSv/MBq.

253 e effective total-body dose was 7.80E-03 mSv/MBq.

254 15E-03 mSv/MBq) and red marrow (8.49E-04 mSv/MBq).

255 tive dose of (18)F-PF-06684511 was 0.043 mSv/MBq for humans.

256 terest were the bladder (0.102 +/- 0.046 mSv/MBq) and kidneys (0.029 +/- 0.009 mSv/MBq).

257 r wall (0.38 mSv/MBq) and kidneys (0.054 mSv/MBq).

258 a mean effective dose of 0.029 +/- 0.06 mSv/MBq, with the highest organ dose to the pancreas (0.274

259 average effective dose of 0.54 +/- 0.07 mSv/MBq.

260 an dose to the pancreas (0.274 +/- 0.099 mSv/MBq).

261 479 mSv), and the parotid glands (0.1137 mSv/MBq).

262 ls (0.1835 mSv/MBq), the kidneys (0.1722 mSv/MBq), the submandibular glands (0.1479 mSv), and the par

263 radioactivity were the adrenals (0.1835 mSv/MBq), the kidneys (0.1722 mSv/MBq), the submandibular gl

264 for (124)I-omburtamab was 0.49 +/- 0.27 mSv/MBq.

265 ose per patient was 0.9 mSv/MBq (SD, 0.3 mSv/MBq).

266 oses were the urinary bladder wall (0.38 mSv/MBq) and kidneys (0.054 mSv/MBq).

267 mean effective dose per patient was 0.9 mSv/MBq (SD, 0.3 mSv/MBq).

268 doses in source organs ranged from 7.7 muGy.MBq(-1) in the brain to 12.7 muGy.MBq(-1) in the spleen.

269 m 7.7 muGy.MBq(-1) in the brain to 12.7 muGy.MBq(-1) in the spleen.

270 The highest organ-absorbed doses (muGy/MBq) after oral (18)F-FDG administration were observed f

271 +/- SD) effective dose was 22.0 +/- 1.0 muSv/MBq.

272 le-body effective dose was 33.3 +/- 2.1 muSv/MBq for an adult female and 33.1 +/- 1.4 muSv/MBq for an

273 ve dose was determined to be 33.3+/-2.1 muSv/MBq for an adult female and 33.1+/-1.4 muSv/MBq for an a

274 the effective dose was estimated at 17 muSv/MBq.

275 r wall as the dose-critical tissue (185 muSv/MBq), followed by the kidneys (23 muSv/MBq).

276 16612 in humans was calculated to be 22 muSv/MBq, which is typical for (18)F-labeled radioligands.

277 muSv/MBq), followed by the kidneys (23 muSv/MBq).

278 /MBq for an adult female and 33.1+/-1.4 muSv/MBq for an adult male with a 1.5 hour urinary bladder vo

279 Bq for an adult female and 33.1 +/- 1.4 muSv/MBq for an adult male, with a 1.5-h urinary bladder void

280 he liver (43.1 +/- 4.9 and 68.9 +/- 9.4 muSv/MBq in reference human male and female phantoms, respect

281 8.70 muSv/MBq), kidneys (9.56 +/- 2.46 muSv/MBq), liver (8.94 +/- 1.67 muSv/MBq), and spleen (9.49 +

282 ry profile (effective dose of 20.5-24.5 muSv/MBq).

283 ivalent was 6.9 +/- 0.6 and 8.7 +/- 0.6 muSv/MBq, respectively.

284 ed mean effective dose was 12.8 +/- 0.6 muSv/MBq.

285 n a mean effective dose of 12.8 +/- 0.6 muSv/MBq.

286 /- 2.46 muSv/MBq), liver (8.94 +/- 1.67 muSv/MBq), and spleen (9.49 +/- 3.89 muSv/MBq).

287 se for (11)C-nicotine was 5.44 +/- 0.67 muSv/MBq.

288 he total absorbed body dose was low (<7 muSv/MBq); the effective dose was estimated at 17 muSv/MBq.

289 he urinary bladder wall (14.68 +/- 8.70 muSv/MBq), kidneys (9.56 +/- 2.46 muSv/MBq), liver (8.94 +/-

290 67 muSv/MBq), and spleen (9.49 +/- 3.89 muSv/MBq).

291 factors were 6.7, 9.4, 13.3, and 19.3 Gy per MBq/mL and kidneys were 7.1, 10.3, 15.0, and 22.0 Gy per

292 ined to be 11.0, 12.1, 13.6, and 15.2 Gy per MBq/mL at image times of 24, 48, 72, and 96 h, respectiv

293 ined to be 11.0, 12.1, 13.6, and 15.2 Gy per MBq/mL at image times of 24, 48, 72, and 96 hours, respe

294 factors were 6.7, 9.4, 13.3, and 19.3 Gy per MBq/mL at those times, and kidneys were 7.1, 10.3, 15.0,

295 idneys were 7.1, 10.3, 15.0, and 22.0 Gy per MBq/mL at those times.

296 idneys were 7.1, 10.3, 15.0, and 22.0 Gy per MBq/mL.

297 erall absorbed dose to the normal organs per MBq of (131)I administered, between the 2 TSH stimulatio

298 n patients received 325 +/- 29 (mean +/- SD) MBq of the cyclotron-produced (99m)Tc-NaTcO4, whereas th

299 3)I-MIBG injection (191 +/- 41 [mean +/- SD] MBq).

300 ubstantially higher (e.g., 7.47 vs. 1.96 uGy/MBq at 200 mm(3)) than that of (177)Lu-PSMA I&T.